Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080899 · ClinicalTrials.gov registry record · Phase 2
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00080899: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00080899 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080899, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die
Interventions
- OTHER laboratory biomarker analysis
- DRUG fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080899
The ClinicalTrials.gov registry entry for NCT00080899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00080899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080899 about?
NCT00080899 is a clinical study titled "Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer". This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer. Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so th...
What is the current status of trial NCT00080899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00080899?
The interventions under investigation include: laboratory biomarker analysis (OTHER), fenretinide (DRUG).
Who is sponsoring clinical trial NCT00080899?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.